TORL
is a California-based biotechnology company that researches and develops novel and antibody-based therapeutics for the treatment of cancer... Read moreTORL
is a California-based biotechnology company that researches and develops novel and antibody-based therapeutics for the treatment of cancer... Read more
Chairman & CEO
Mark J. Alles
News
Sep 15, 2024
StreetInsider
Press Release: TORL : TORL BioTherapeutics Presents Updated Phase 1 Results of Novel Claudin 6 Targeted Antibody-Drug Conjugate TORL-1-23 at the 2024 European Society of Medical Oncology Congress
May 17, 2024
ExploreBit
TORL: TORL BioTherapeutics Raises USD 158M Series B2 Financing
May 07, 2024
Global Legal Chronicle
TORL: TORL BioTherapeutics' $158 Million Series B-2 Financing
Apr 15, 2024
Silicon Valley Investclub
TORL: TORL BioTherapeutics Raises $158 Million in Funding
Apr 12, 2024
MedCity News
TORL: Another ADC Developer Lands a Mega Round of Financing for Cancer Clinical Trials
Apr 12, 2024
BioCentury
TORL: Venture report: Torl doubles its series B funding in Deep Track-led B2
Apr 11, 2024
Pharmaceutical Business Review
TORL: TORL BioTherapeutics secures $158m for oncology pipeline development
Apr 10, 2024
FinSMEs
TORL: TORL BioTherapeutics Raises $158M in Series B-2 Financing
Apr 10, 2024
Endpoints News
TORL: Another ADC biotech reels in big bucks as Mark Alles' TORL nabs $158M
Apr 10, 2024
Pharamceutical Technology
TORL: TORL scores $158m in Series B2 to advance ADC cancer therapies
